The DUSP3 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human liver adenocarcinoma SK-HEP-1 cell line, designed to disrupt DUSP3 gene expression. This loss-of-function model provides a heterogeneous pool of cells with targeted gene disruption, enabling functional studies without the need for single-cell clone isolation. The polyclonal format offers a robust system for investigating DUSP3-dependent phenotypes in a hepatic adenocarcinoma background, suitable for professional research applications.
SK-HEP-1 is a well-characterized human liver adenocarcinoma epithelial cell line originally isolated from the ascites of a patient with adenocarcinoma. Widely used as a hepatocellular carcinoma model, SK-HEP-1 cells retain many features of hepatic tumor cells, including epithelial morphology and malignant properties such as anchorage-independent growth and tumorigenicity in xenograft assays. This cell line is particularly relevant for studying liver cancer biology, including apoptosis resistance, metastasis, and drug response, making it an appropriate host for DUSP3 loss-of-function analysis in a disease-relevant context.
DUSP3 (dual specificity phosphatase 3) functions as a negative regulator of MAP kinase signaling by dephosphorylating both phosphotyrosine and phosphoserine/threonine residues on key kinases, notably ERK1/2 and JNK. Under normal conditions, DUSP3 transcription is activated by p53 and oxidative stress via reactive oxygen species (ROS), thereby providing feedback control over MAPK pathway activity. By dephosphorylating ERK1/2 and JNK, DUSP3 attenuates downstream signaling cascades that regulate transcription factors such as Elk-1 and c-Jun. In the absence of DUSP3, these kinases remain hyperphosphorylated, leading to sustained activation of ERK and JNK pathways, increased transcription of target genes, and enhanced cell cycle progression and survival signaling.
In the SK-HEP-1 hepatic adenocarcinoma context, DUSP3 acts as a potential tumor suppressor, and its disruption is anticipated to exacerbate oncogenic phenotypes. Loss of DUSP3 function in these cells is expected to increase basal and stimulated phosphorylation of ERK1/2 and JNK, thereby promoting proliferation, migration, invasion, and clonogenic growth. This model enables the systematic assessment of how DUSP3 deficiency influences hepatocellular carcinoma cell behavior, providing insight into the role of phosphatase-mediated regulation in liver tumorigenesis. The interplay between DUSP3 and MAPK signaling components makes this knockout system particularly valuable for dissecting pathway dependencies and identifying therapeutic vulnerabilities in liver cancer.
Key research applications include investigating DUSP3 tumor suppressor mechanisms in hepatocellular carcinoma, delineating MAPK pathway feedback regulation, and performing drug sensitivity screens targeting ERK or JNK cascades. Assays such as Western blotting for phospho-ERK1/2 and phospho-JNK, RT-qPCR for DUSP3 transcript, and functional assays including MTT/BrdU proliferation, Annexin V/PI apoptosis, transwell migration/invasion, and colony formation are suitable for phenotypic analysis. This polyclonal knockout product also supports biomarker discovery and validation studies in liver cancer. For further information, technical support, or custom inquiries, please contact Ascent Research.
